Alzheimer’s Disease: Dynamic Market Forecast to 2026Potential first humanized monoclonal antibody for the treatment of AD could enter in the market in 2021Approval and launch of DMT classes will revolutionize the field of AD therapeutics, regardless of their cost and increase competitionThree of BACE1 inhibitors have been terminated since September 2017 so elenbecestat is now leading this class due to recently published positive data resultsCombination of treatment with CNP520 and CAD106 from Novartis could open new option for the treatment of ADLaunch of new four pipeline drugs added in the late stage pipelineScope
Alzheimer’s Disease: Dynamic Market Forecast to 2026, research report is designed to help clients stay abreast of the latest news in the Alzheimer’s Disease (AD) space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.
Alzheimer’s Disease (AD) is a rapidly evolving field in which new developments are constantly influencing the market landscape.
The Dynamic Market Forecast consists of a slide deck detailing key market-impacting events that have occurred in the Alzheimer’s Disease (AD) Space which reflects the projected influence of these events on the future AD market.
The Key Events covered in this Alzheimer’s Disease (AD) Dynamic Market Forecast include -
Components of the slide deck include - Timeline of market-impacting eventsKey clinical trial landscape updatesDetailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspectiveOverview of updates to the forecast model based on anticipated future impact of eventsForward-looking events calendar listing expected key updates to the AD competitive space through October2018 - October 2021
Other events included in the analysis include - Regulatory filingsApproval decisionsPricing changesPatent litigationClinical trial data announcementsClinical trial failuresClinical trial timeline updatesReasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- 1. Dynamic Market Forecast Overview 5
- 1.1 Related Reports 6
- 1.2 Upcoming Related Reports 7
- 2. Executive Summary 8
- 2.1 Key Updates to AD Market Dynamics 9
- 2.1 Key Events in Update 10-13
- 2.2 Clinical Trial Landscape Updates 14-15
- 2.3 Pipeline Landscape Updates 16
- 2.4 Market Insight on Key Events 17
- 3. Event 1: Approval and Launch of DMD Classes Will Revolutionize the Field of AD Therapeutics, Regardless of Their Cost 18
- 3.1 Key Updates to the Monoclonal Antibodies Market Dynamics 19
- 3.2 Biogen, Aducanumab 20-21
- 3.3 What Do Physicians Think? 22
- 3.4 Roche, Crenezumab 23
- 3.5 What Do Physicians Think? 24
- 3.6 Roche, Gantenerumab 25
- 3.7 What Do Physicians Think? 26
- 3.8 Competitive Landscape of Monoclonal Antibodies in AD 27
- 3.9 Summary/Trends 28
- 3.10 Sources 29
- 4. Event 2: Recent failures of large late-phase trials have cast doubts over AD drug developers 30
- 4.1 Key Updates to BACE Inhibitors and Combination with Vaccines Market Dynamics 31
- 4.2 BACE1 Discontinued in 2018 Based on Toxicity and Efficacy Concerns 32
- 4.3 Eisai, Elenbecestat 33
- 4.4 What Do Physicians Think? 34
- 4.5 Novartis, CNP520 35
- 4.6 What Do Physicians Think? 36
- 4.7 Novartis, CAD106 37
- 4.8 What Do Physicians Think? 38
- 4.9 Competitive Landscape of BACE Inhibitors and Combination with Vaccines in AD 39
- 4.10 Summary/Trends 40
- 4.11 Sources 41
- 5. Events Calendar 42
- 5.1 Key Events Expected to Occur in 2018-2021 43
- 6. Appendix 44
- 6.1 Methodology 45
- 6.2 Primary Research 46
- 6.3 About the Authors 47-49
- 6.4 About GlobalData 50
- 6.5 Contact Us 51
- 6.6 Disclaimer 52